OCT1 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin inhibits OCT1 indirectly by activating the pregnane X receptor (PXR), which leads to the induction of CYP3A4. The increased CYP3A4 activity metabolizes endogenous substances that would otherwise inhibit OCT1, indirectly alleviating its inhibition. T | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil inhibits OCT1 directly by competing for binding sites, thereby reducing its substrate binding and uptake. This direct inhibition showcases the competitive nature of substrate binding to OCT1, offering insights into the structural aspects of interactions with small molecules. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Quinine inhibits OCT1 directly by competing for binding sites, impeding the substrate binding and uptake. This direct inhibition underscores the competitive dynamics of substrate binding to OCT1, providing insights into the structural aspects of interactions with small molecules. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits OCT1 directly by interacting with its substrate-binding sites, leading to reduced substrate uptake. This direct inhibition highlights the specific molecular interactions that can modulate OCT1 activity, offering insights into the potential of targeted therapeutics in influencing its function. | ||||||
1-Adamantylamine | 768-94-5 | sc-251475 sc-251475A | 1 g 25 g | $39.00 $147.00 | ||
Amantadine inhibits OCT1 directly by interfering with substrate binding, resulting in reduced uptake. This direct inhibition exemplifies the impact of small molecules on the substrate-binding pockets of OCT1, offering insights into the structural determinants of inhibition. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine inhibits OCT1 directly by competing for substrate binding, leading to decreased substrate uptake. This direct inhibition sheds light on the competitive dynamics of substrate interactions with OCT1, providing insights into the structural aspects of inhibition. | ||||||
Mepyramine maleate | 59-33-6 | sc-203629 sc-203629A | 100 mg 1 g | $66.00 $224.00 | 1 | |
Mepyramine maleate inhibits OCT1 directly by interfering with substrate binding, resulting in reduced substrate uptake. This direct inhibition exemplifies the impact of small molecules on the substrate-binding pockets of OCT1, offering insights into the structural determinants of inhibition. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $67.00 $161.00 $255.00 $721.00 $3401.00 | 4 | |
Trimethoprim inhibits OCT1 directly by competing for substrate binding, leading to reduced substrate uptake. This direct inhibition highlights the competitive dynamics of substrate interactions with OCT1, providing insights into the structural aspects of inhibition. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Chlorpromazine inhibits OCT1 directly by interfering with substrate binding, resulting in reduced substrate uptake. This direct inhibition exemplifies the impact of small molecules on the substrate-binding pockets of OCT1, offering insights into the structural determinants of inhibition. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol inhibits OCT1 directly by competing for substrate binding, leading to reduced substrate uptake. This direct inhibition showcases the competitive dynamics of substrate interactions with OCT1, providing insights into the structural aspects of inhibition. | ||||||